Draft:Nutcracker Therapeutics

Nutcracker Therapeutics is a biotechnology company based in Emeryville, CA that develops mRNA-based oncology therapeutics using a proprietary microfluidics-based manufacturing technology. The company was founded in 2018 by Igor Khandros, Ph.D., and Benjamin Eldridge. Khandros currently serves as chief executive officer, with Eldridge as chief technology officer.

NTX-250, Nutcracker’s lead candidate, is a multimodal RNA therapeutic primarily for use against the HPV-driven cervical cancer precursor, cervical intraepithelial neoplasia. As of 2023, NTX-250 is in the preclinical stage of development.